Medtronic plans $650M SPR Therapeutics acquisition

Medtronic said on May 20, 2026, that it plans to acquire SPR Therapeutics for about $650 million in cash, adding SPR’s FDA-cleared SPRINT peripheral nerve stimulation system to its neuromodulation business. The deal would bring Medtronic a temporary, 60-day peripheral nerve stimulation option for chronic pain that doesn’t require a permanent implant, broadening its pain portfolio beyond longer-term implantable therapies. Medtronic said SPR will remain a separate company until the transaction closes, which is expected in the first half of Medtronic’s fiscal 2027. (nasdaq.com)

Why it matters: For veterinary professionals, this is another sign that large medtech companies see continued growth in less invasive neuromodulation for pain care. While SPR’s system is cleared for use in adults, not veterinary patients, the strategy matters because it underscores a broader shift toward earlier-intervention, drug-sparing pain technologies, an area that could continue shaping expectations around multimodal pain management, referral pathways, and future translational interest in animal health. SPR said it reached 50,000 implants of the SPRINT system in December 2025, suggesting meaningful clinical uptake before the acquisition announcement. (nasdaq.com)

What to watch: Watch for closing details in the first half of Medtronic’s fiscal 2027, and for how quickly Medtronic integrates SPRINT into its broader pain and neuromodulation commercial strategy. (massdevice.com)